PRGO Stock Recent News

Perrigo Company focuses on the consumer self-care market and aligns with the growing trend of investing in well-being products. The company has faced regulatory issues with its baby formula production, leading to FDA warning letters and recalls. Appointing a new CEO and implementing a strategic plan to increase organic net sales and improve shareholder value may present a buying opportunity, but execution risks should be considered.

Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales.

Perrigo Co. Plc's stock PRGO, -0.97% fell 14% early Tuesday, after the consumer self-care and wellness products maker posted weaker-than-expected third-quarter sales and lowered its guidance. Dublin, Ireland-based Perrigo had net income of $14.2 million, or 10 cents a share, for the quarter, after a loss of $49.4 million, or 37 cents a share, in the year-earlier period.

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Broadcom Inc. and Perrigo Company plc are two companies providing impressive dividend growth to their shareholders. Perrigo Company is a smaller pharmaceutical company focusing on over-the-counter healthcare products, while Broadcom is a semiconductor behemoth with a software business segment set to grow. Both are expecting attractive growth going forward, which could further support even more dividend growth and possibly capital appreciation in the future.

DUBLIN , Oct. 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2023 financial results on Tuesday, November 7, 2023, and will host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 0043209.

The U.S. Food and Drug Administration said Wednesday it has sent warning letters to three baby-formula makers as part of what the agency called enhanced oversight of the product, which was plagued by numerous recalls and shortages last year.

Perrigo Company plc provides over-the-counter health and wellness solutions after recently divesting its prescription businesses. Perrigo stock is reasonably valued at under 14 times forward earnings with a 3% dividend yield. Time to Buy, Sell, or Hold?  An analysis follows below.

DUBLIN , Aug. 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that CFO Eduardo Bezerra is scheduled to participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7 th, 2023. Separately, President and CEO, Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Piper Sandler Growth Frontiers Conference in Nashville, TN on Tuesday, September 12 th, 2023, at 11:00 AM EDT.

Perrigo Company plc (NYSE:PRGO ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Taylor - President and Chief Executive Officer Eduardo Bezerra - Executive Vice President and Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Alec Legg - Canaccord Genuity Daniel Biolsi - Hedgeye Operator Good Day and welcome to the Perrigo Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.